On November 3, 2025 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, reported that five abstracts – one oral and four poster presentations – have been accepted for presentation at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) 2025 Annual Meeting, to be held December 6-9, 2025 in Orlando, FL. The data feature new clinical and translational analyses of RYTELO (imetelstat) across lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and myelofibrosis (MF).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The ASH (Free ASH Whitepaper) 2025 presentations reflect growing scientific momentum around imetelstat and telomerase inhibition," said Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron. "Across multiple analyses, we continue to see evidence of imetelstat’s potential to deliver durable and biologically meaningful outcomes in both lower-risk MDS and myelofibrosis. We look forward to presenting these data and continuing to inform physicians and patients on the benefits of RYTELO."

Accepted Presentations

Oral Presentation (LR-MDS)

Abstract #490: Correlation between Treatment-Emergent Cytopenias and Clinical Response with Imetelstat (IME) in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS): Analysis from the IMerge Trial
Presenter : Amer Zeidan, MBBS, MHS, Chief of the Division of Hematologic Malignancies and Professor of Medicine at Yale University
Presentation Date and Time: December 7, 2025, 10:00-10:15 AM ET
"In hematology, the emergence of cytopenias can reflect a therapy’s biological activity within the bone marrow," said Amer Zeidan, Chief of the Division of Hematologic Malignancies and Professor of Medicine at Yale University. "Our analysis explores how early treatment-emergent cytopenias with imetelstat are on target and may relate to clinical response, helping to inform how we interpret treatment patterns and patient management in this setting. Together with other studies being presented at ASH (Free ASH Whitepaper), these findings continue to build a deeper scientific understanding of telomerase inhibition and its relevance in myeloid malignancies."

Poster Presentation (LR-MDS)

Publication #2074: Long-Term Outcomes from Randomized, Double-Bind, Placebo-Controlled, Phase 3 IMerge Trial of Imetelstat for Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Presenter: Valeria Santini, M.D., Associate Professor of Hematology at the University of Florence Medical School
Session Date and Time: December 6, 2025, 5:30 PM – 7:30 PM ET
This abstract evaluates long-term follow-up data from the IMerge trial, which is the foundation of imetelstat’s approval in the U.S. and EU. Although the 42-month landmark analysis was not pre-specified, the totality of the data and the results of an overall survival OS analysis (≥42 months) suggest a favorable trend for imetelstat in OS, progression-free survival and time to progression to AML, compared to placebo.

Poster Presentations (MF)

Publication #5585: Correlation between Interleukin (IL)-8 and Tumor Necrosis Factor (TNF)-Alpha Levels and Overall Survival in Patients (Pts) with Myelofibrosis (MF) Relapsed or Refractory (R/R) to a Janus-Associated Kinase Inhibitor (JAKi) Treated with Imetelstat (IME) in the IMbark Trial
Presenter: John Mascarenhas, M.D., Professor of Medicine at the Icahn School of Medicine at Mount Sinai
Session Date and Time: December 8, 2025, 6:00 PM – 8:00 PM ET
This abstract is a new exploratory analysis using data from the Phase 2 IMbark trial of imetelstat in relapsed/refractory MF. This hypothesis-generating analysis identified dose-dependent reductions in specific inflammatory cytokines with imetelstat from baseline which, taken together with previously presented data, suggests potential disease-modifying activity in MF.

Publication #2052: IMproveMF: Phase 1b Trial of Imetelstat Plus Ruxolitinib in Patients with Intermediate-2 or High-Risk Myelofibrosis
Presenter: John Mascarenhas, M.D., Professor of Medicine at the Icahn School of Medicine at Mount Sinai
Session Date and Time: December 6, 2025, 5:30 PM – 7:30 PM ET
This abstract is sharing the trial design for the expansion portion of the IMproveMF Phase 1b trial of imetelstat and ruxolitinib in high-risk MF. The first treatment visit has occurred, and enrollment is ongoing.

Poster Presentation (Investigator Sponsored: HR-MDS and AML)

Publication #5115: A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-based Therapy: Interim Analysis Results of the IMpress Study
Presenter: Lionel Ades, M.D., Ph.D., Professor of Hematology, Paris University – Hospital Saint-Louis
Session Date and Time: December 8, 2025, 6:00 – 8:00 PM ET
This abstract presents interim results from an investigator-led study exploring imetelstat in high-risk MDS. The results suggest that imetelstat has limited single agent activity in this group, with one patient remaining on study.

Dr. Zeidan has served as a consultant for Geron and has received honoraria. The views expressed in this press release and in the presentation are his own and do not necessarily reflect those of his employer.

(Press release, Geron, NOV 3, 2025, View Source [SID1234659257])